Pluri (PLUR) Net Income towards Common Stockholders Growth (1y) (2011 - 2025)
Pluri (PLUR) Net Income towards Common Stockholders Growth (1y) (2011 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
-58.11% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
104.24% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
-290.15% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
-129.68% |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
-230.18% |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
59.59% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Pluri |
20.93 Mn |
21.41 Mn |
86,000.00 |
62.24% |
| Date | Value |
|---|
| Dec 31, 2025 |
62.24% |
| Sep 30, 2025 |
46.48% |
| Jun 30, 2025 |
-9.63% |
| Mar 31, 2025 |
2.43% |
| Dec 31, 2024 |
113,017.74% |
| Sep 30, 2024 |
109,852.23% |
| Jun 30, 2024 |
-194.64% |
| Mar 31, 2024 |
-174.14% |
| Dec 31, 2023 |
171.18% |
| Sep 30, 2023 |
169.71% |
| Jun 30, 2023 |
174.38% |
| Mar 31, 2023 |
174.06% |
| Dec 31, 2022 |
36.16% |
| Sep 30, 2022 |
37.79% |
| Jun 30, 2022 |
39.11% |
| Mar 31, 2022 |
26.36% |
| Dec 31, 2021 |
17.43% |
| Sep 30, 2021 |
-30.95% |
| Jun 30, 2021 |
-71.33% |
| Mar 31, 2021 |
-92.26% |
